BCL2 and lymphoma: Even in patients initially treated with rituximab, the present results suggest an increased rate of lymphoma-related death beyond 10 years if prevalent nonsynonymous BCL2 mutations are present at diagnosis (Fig. 3B, blue solid line), raising the possibility that increased drug resistance in later-line therapy might provide an explanation for the separation between the two survival curves in Fig. 3C.